Kyle Guse - Net Worth and Insider Trading

Kyle Guse Net Worth

The estimated net worth of Kyle Guse is at least $1,245 dollars as of 2024-04-30. Kyle Guse is the CFO, Gen Counsel and Secretary of Atossa Therapeutics Inc and owns about 833 shares of Atossa Therapeutics Inc (ATOS) stock worth over $1,245. Details can be seen in Kyle Guse's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kyle Guse has not made any transactions after 2017-11-15 and currently still holds the listed stock(s).

Transaction Summary of Kyle Guse

To

Kyle Guse Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kyle Guse owns 1 companies in total, including Atossa Therapeutics Inc (ATOS) .

Click here to see the complete history of Kyle Guse’s form 4 insider trades.

Insider Ownership Summary of Kyle Guse

Ticker Comapny Transaction Date Type of Owner
ATOS Atossa Therapeutics Inc 2017-11-15 CFO & General Counsel

Kyle Guse Latest Holdings Summary

Kyle Guse currently owns a total of 1 stock. Kyle Guse owns 833 shares of Atossa Therapeutics Inc (ATOS) as of November 15, 2017, with a value of $1,245.

Latest Holdings of Kyle Guse

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ATOS Atossa Therapeutics Inc 2017-11-15 833 1.50 1,245

Holding Weightings of Kyle Guse


Kyle Guse Form 4 Trading Tracker

According to the SEC Form 4 filings, Kyle Guse has made a total of 0 transactions in Atossa Therapeutics Inc (ATOS) over the past 5 years. The most-recent trade in Atossa Therapeutics Inc is the acquisition of 833 shares on November 15, 2017, which cost Kyle Guse around $3,400.

Insider Trading History of Kyle Guse

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kyle Guse Trading Performance

GuruFocus tracks the stock performance after each of Kyle Guse's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kyle Guse is 105.71%. GuruFocus also compares Kyle Guse's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kyle Guse within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Kyle Guse's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Kyle Guse

Average Return

-67.49%

Average return per transaction

Outperforming Transactions

0%

0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -3.23 105.71 -3.47 -67.49 -41.27 -26.99
Relative Return to S&P 500(%) -7.57 99.21 -9.2 -73.95 -51.58 -38.82

Kyle Guse Ownership Network

Ownership Network List of Kyle Guse

No Data

Ownership Network Relation of Kyle Guse


Kyle Guse Owned Company Details

What does Atossa Therapeutics Inc do?

Who are the key executives at Atossa Therapeutics Inc?

Kyle Guse is the CFO & General Counsel of Atossa Therapeutics Inc. Other key executives at Atossa Therapeutics Inc include SVP & Finance and Accounting Heather Rees , director & 10 percent owner & Chief Scientific Officer Shu-chih Chen , and director & 10 percent owner & CEO Steven C Quay .

Atossa Therapeutics Inc (ATOS) Insider Trades Summary

Over the past 18 months, Kyle Guse made no insider transaction in Atossa Therapeutics Inc (ATOS). Other recent insider transactions involving Atossa Therapeutics Inc (ATOS) include a net sale of 0 shares made by Gregory L Weaver , and a net purchase of 25,000 shares made by Jonathan Finn .

In summary, during the past 3 months, insiders sold 0 shares of Atossa Therapeutics Inc (ATOS) in total and bought 25,000 shares, with a net purchase of 25,000 shares. During the past 18 months, 50,000 shares of Atossa Therapeutics Inc (ATOS) were sold and 75,000 shares were bought by its insiders, resulting in a net purchase of 25,000 shares.

Atossa Therapeutics Inc (ATOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Atossa Therapeutics Inc Insider Transactions

No Available Data

Kyle Guse Mailing Address

Above is the net worth, insider trading, and ownership report for Kyle Guse. You might contact Kyle Guse via mailing address: C/o Atossa Genetics Inc., 1616 Eastlake Ave. E Suite 510, Seattle Wa 98102.

Discussions on Kyle Guse

No discussions yet.